CSPC Pharmaceutical Group Limited (CVG.F)

0,7500 0,0000 (0,00%) Börsenschluss: 08:04AM CEST

CSPC Pharmaceutical Group Limited

No. 226 Huanghe Street
Shijiazhuang 050035
China
86 31 1870 37015
https://www.cspc.com.hk

Sektor(en): Healthcare
Branche: Drug Manufacturers - General
Vollzeitmitarbeiter: 23.500

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Dongchen Cai	Executive Chairman	2,38M	N/A	1954
Mr. Cuilong Zhang	Vice-Chairman, Executive Director & CEO	1,26M	N/A	1969
Mr. Chunlei Li	Executive Director & Chief Scientist	860,75k	N/A	1976
Mr. Weidong Pan	Executive Director	457,48k	N/A	1969
Mr. Huaiyu Wang	Executive Director	562,31k	N/A	1963
Mr. Zhenguo Wang	Executive Director	455,3k	N/A	1970
Dr. Hao Jiang	Executive Director	341,99k	N/A	1984
Mr. Xin Cai	Group Executive President, President of the Group's Marketing Strategy Division & Executive Director	N/A	N/A	1991
Mr. Bing Yao	Executive Director	N/A	N/A	1977
Mr. Tai On Lo CPA	Company Secretary	N/A	N/A	1954

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, North America, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company has a strategic partnership with Pfizer Inc. to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

Corporate Governance

CSPC Pharmaceutical Group Limiteds ISS Governance QualityScore, Stand 1. Juni 2024, lautet 8. Die grundlegenden Scores sind Audit: 7, Vorstand: 5, Shareholderrechte: 4, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.